Brodalumab-Induced Eczematous Reactions in Psoriasis Patients: Management With Switching to Risankizumab.
J Cutan Med Surg
; 27(3): 236-240, 2023.
Article
em En
| MEDLINE
| ID: mdl-37014149
ABSTRACT
Biological treatments targeting IL-17 are highly efficacious with rapid onset of action in psoriasis. Cutaneous adverse events are associated with different biological treatments, including paradoxical psoriasis and eczematous reactions. Brodalumab was previously suggested as an alternative treatment option in psoriasis patients who developed dermatitis or paradoxical psoriasis while on a biologic. Here we report three psoriasis patients who developed brodalumab induced eczematous reaction with complete clearance after switching to risankizumab. Early recognition is crucial for appropriate management. We propose switching patients with psoriasis who develop severe eczematous reaction while on a biologic targeting IL-17 to an IL 23 inhibitor due to efficacy in psoriasis and rarely reported eczematous reaction.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Psoríase
/
Produtos Biológicos
/
Eczema
Limite:
Humans
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article